BDX vs DXCM
Becton Dickinson & Co (BDX) and Dexcom Inc (DXCM) are both filed with the SEC under Surgical & Medical Instruments & Apparatus. BDX is 1.5× DXCM's size by market cap ($51.2B against $33.7B); DXCM trades at the higher fiscal-year P/E (42.7× against 32.3×); DXCM reports the higher net margin (17.9% against 7.7%); DXCM grew sales faster over three years (+17.0% against +5.0%); and over the past year BDX returned +28.2% against DXCM's +21.0%.
| BDX | DXCM | |
|---|---|---|
| Last close | $189.52 | $90.82 |
| Market cap | $51.2B | $33.7B |
| P/E (FY) | 32.3× | 42.7× |
| P/S | 2.3× | 7.2× |
| EV/EBITDA | 13.8× | — |
| Gross margin | — | 60.1% |
| Operating margin | 11.8% | 19.6% |
| Net margin | 7.7% | 17.9% |
| Return on equity | 6.5% | 34.5% |
| Sales growth (3y) | +5.0% | +17.0% |
| EPS growth (3y) | -0.3% | +36.6% |
| Dividend yield | 2.3% | — |
| 1-year return | +28.2% | +21.0% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: BDX FY2025 (ended 2025-09-30); DXCM FY2025 (ended 2025-12-31). — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| BDX | DXCM | |
|---|---|---|
| Institutional holders (13F) | 1,454 | 953 |
| Insider buyers − sellers (180d) | -3 | -5 |
| Congressional trades disclosed (180d) | 3 | 2 |
| Executive-branch officials on file — trades disclosed (180d) | 4 | 9 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
BDX vs DXCM: common questions
- Is BDX bigger than DXCM?
- BDX carries the larger market cap — $51.2B against $33.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, BDX or DXCM?
- DXCM, at a fiscal-year 42.7× against 32.3× for BDX. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have BDX and DXCM performed over the past year?
- BDX returned +28.2% and DXCM +21.0%, measured on the trailing calendar year to the last close.
- How many institutions hold BDX and DXCM?
- 1,454 13F filers report a position in BDX and 953 in DXCM, on the latest quarter in the panel.
- Are BDX and DXCM in the same industry?
- Both are filed with the SEC under Surgical & Medical Instruments & Apparatus, which is the classification this pairing is built on.
BDX overview → · DXCM overview → · BDX institutional ownership → · DXCM institutional ownership → · Congress and BDX → · Congress and DXCM → · Executive branch and BDX → · Executive branch and DXCM →
More in Surgical & Medical Instruments & Apparatus: BDX vs BSX · BDX vs MMM · BDX vs RMD · BDX vs SYK
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/bdx-vs-dxcm